Abstract
In this review an overview of the application of computational approaches is given. Specifically, the uses of Quantitative Structure-Activity Relationship (QSAR) methods for in silico identification of new families of compounds as novel tyrosinase inhibitors are revised. Assembling, validation of models through prediction series, and virtual screening of external data sets are also shown, to prove the accuracy of the QSAR models obtained with the TOMOCOMD-CARDD (TOpological MOlecular COMputational Design- Computer-Aided Rational Drug Design) software and Linear Discriminant Analysis (LDA) as statistical technique. Together with this, a database is collected for these QSAR studies, and could be considered a useful tool in future QSAR modeling of tyrosinase activity and for scientists that work in the field of this enzyme and its inhibitors. Finally, a translation to real world applications is shown by the use of QSAR models in the identification and posterior in-vitro evaluation of different families of compounds. Several different classes of compounds from various sources (natural and synthetic) were identified. Between them, we can find tetraketones, cycloartanes, ethylsteroids, lignans, dicoumarins and vanilloid derivatives. Finally, some considerations are discussed in order to improve the identification of novel drug-like compounds based on the use of QSAR-Ligand-Based Virtual Screening (LBVS).
Keywords: Tyrosinase Inhibitor, TOMOCOMD-CARDD, Quantitative Structure-Activity Relationship (QSAR), Ligand-Based Virtual Screening (LBVS), Linear Discriminant Analysis (LDA), melanin hyperpigmentation, Melanogenesis, ligand-guided drug design, neuro-informatics, molecular descrip-tors (MDs), Dragon software, kojic acid tripeptides, novel N-substituded N-nitrosohydroxylamines, STATISTICA, BIOACTIVITY CONVERGENCE, Atom-Based Bilinear Indices, Wilks, ’, statistics, non-stochastic bilinear indices, Anti-Tyrosinase Activity, LBVS, Atom-Based Quadratic Indices, QSAR-LDA, Lignan Family, Cluster Analysis, K-means cluster analysis, Matthews´correlation coefficient
Current Pharmaceutical Design
Title: Ligand-Based Computer-Aided Discovery of Tyrosinase Inhibitors. Applications of the TOMOCOMD-CARDD Method to the Elucidation of New Compounds
Volume: 16 Issue: 24
Author(s): Yovani Marrero-Ponce, Gerardo M. Casanola-Martin, Mahmud Tareq Hassan Khan, Francisco Torrens, Antonio Rescigno and Concepcion Abad
Affiliation:
Keywords: Tyrosinase Inhibitor, TOMOCOMD-CARDD, Quantitative Structure-Activity Relationship (QSAR), Ligand-Based Virtual Screening (LBVS), Linear Discriminant Analysis (LDA), melanin hyperpigmentation, Melanogenesis, ligand-guided drug design, neuro-informatics, molecular descrip-tors (MDs), Dragon software, kojic acid tripeptides, novel N-substituded N-nitrosohydroxylamines, STATISTICA, BIOACTIVITY CONVERGENCE, Atom-Based Bilinear Indices, Wilks, ’, statistics, non-stochastic bilinear indices, Anti-Tyrosinase Activity, LBVS, Atom-Based Quadratic Indices, QSAR-LDA, Lignan Family, Cluster Analysis, K-means cluster analysis, Matthews´correlation coefficient
Abstract: In this review an overview of the application of computational approaches is given. Specifically, the uses of Quantitative Structure-Activity Relationship (QSAR) methods for in silico identification of new families of compounds as novel tyrosinase inhibitors are revised. Assembling, validation of models through prediction series, and virtual screening of external data sets are also shown, to prove the accuracy of the QSAR models obtained with the TOMOCOMD-CARDD (TOpological MOlecular COMputational Design- Computer-Aided Rational Drug Design) software and Linear Discriminant Analysis (LDA) as statistical technique. Together with this, a database is collected for these QSAR studies, and could be considered a useful tool in future QSAR modeling of tyrosinase activity and for scientists that work in the field of this enzyme and its inhibitors. Finally, a translation to real world applications is shown by the use of QSAR models in the identification and posterior in-vitro evaluation of different families of compounds. Several different classes of compounds from various sources (natural and synthetic) were identified. Between them, we can find tetraketones, cycloartanes, ethylsteroids, lignans, dicoumarins and vanilloid derivatives. Finally, some considerations are discussed in order to improve the identification of novel drug-like compounds based on the use of QSAR-Ligand-Based Virtual Screening (LBVS).
Export Options
About this article
Cite this article as:
Marrero-Ponce Yovani, M. Casanola-Martin Gerardo, Tareq Hassan Khan Mahmud, Torrens Francisco, Rescigno Antonio and Abad Concepcion, Ligand-Based Computer-Aided Discovery of Tyrosinase Inhibitors. Applications of the TOMOCOMD-CARDD Method to the Elucidation of New Compounds, Current Pharmaceutical Design 2010; 16 (24) . https://dx.doi.org/10.2174/138161210792389216
DOI https://dx.doi.org/10.2174/138161210792389216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular)
Current Medicinal Chemistry Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets <i>In Silico</i> Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Antidiabetic Potential of Apiaceae Family Plants- A Critical Update
Current Functional Foods Aspects of Matrix Effects in Applications of Liquid Chromatography-Mass Spectrometry to Catecholamine Analysis-A Review
Current Analytical Chemistry HIV-1 Matrix Protein p17 and its Receptors
Current Drug Targets Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Big Data for Treatment Planning: Pathways and Possibilities for Smart Healthcare Systems
Current Medical Imaging An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL)
Current Drug Targets Design and Structure of Peptide and Peptidomimetic Antagonists of Protein- Protein Interaction
Current Protein & Peptide Science MicroRNAs for Diagnosis and Treatment of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Phytochemicals from Peanut (<i>Arachis hypogaea</i> L.) Skin Extract with Potential for Pharmacological Activity
Current Bioactive Compounds Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry